-
公开(公告)号:US20240158823A1
公开(公告)日:2024-05-16
申请号:US18506263
申请日:2023-11-10
CPC分类号: C12P13/02 , C12N9/88 , C12N9/90 , C12N9/93 , C12N15/74 , C12Y402/01011 , C12Y501/01003 , C12Y603/02 , C12Y603/02017 , C12N2800/101 , C12N2800/90
摘要: A genetically modified diazotrophic microbe is genetically modified to produce γ-polyglutamic acid (γ-PGA). In one or more embodiments, the diazotrophic microbe is Azotobacter vinelandii. In one or more embodiments, the diazotrophic microbe is genetically modified to use a non-sugar carbon source.
-
2.
公开(公告)号:US09951336B2
公开(公告)日:2018-04-24
申请号:US14925746
申请日:2015-10-28
发明人: Kobong Choi , Joontae Park , Hyuntae Kang
IPC分类号: C12N15/11 , C12N15/113 , A61K45/06 , A61K31/713
CPC分类号: C12N15/1137 , A61K31/713 , A61K45/06 , C12N2310/11 , C12N2310/14 , C12N2320/30 , C12Y603/02
摘要: A composition for reducing a level of senescence of a cell or subject, a method of reducing a level of senescence in a cell or subject by using the composition, and a method of preventing and treating symptoms or diseases related to or caused by senescence of a cell or subject.
-
公开(公告)号:US09650656B2
公开(公告)日:2017-05-16
申请号:US14390360
申请日:2013-04-03
CPC分类号: C12P17/18 , C07G5/00 , C12N9/0006 , C12N9/0071 , C12N9/1085 , C12N9/93 , C12N15/52 , C12P5/007 , C12Y114/14001 , C12Y205/01 , C12Y603/02
摘要: The biosynthesis of fungal bicyclo[2.2.2]diazaoctane indole alkaloids with a wide spectrum of biological activities have attracted increasing interest. Their intriguing mode of assembly has long been proposed to feature a non-ribosomal peptide synthetase, a presumed intramolecular Diels-Alderase, a variant number of prenyltransferases, and a series of oxidases responsible for the diverse tailoring modifications of their cyclodipeptide-based structural core. Until recently, the details of these biosynthetic pathways have remained largely unknown due to lack of information on the fungal derived biosynthetic gene clusters. Herein, we report a comparative analysis of four natural product metabolic systems of a select group of bicyclo[2.2.2]diazaoctane indole alkaloids including (+)/(−)-notoamide, paraherquamide and malbrancheamide, in which we propose an enzyme for each step in the biosynthetic pathway based on deep annotation and on-going biochemical studies.
-
公开(公告)号:US20170107579A1
公开(公告)日:2017-04-20
申请号:US15170328
申请日:2016-06-01
发明人: Benjamin Stone AMIDON , James E. BROWNELL , James M. GAVIN , Erik M. KOENIG , Michael D. SINTCHAK , Peter G. SMITH
IPC分类号: C12Q1/68 , G01N33/574 , A61K31/519
CPC分类号: C12Q1/6886 , A61K31/519 , C07K16/40 , C12N9/0008 , C12N9/93 , C12Q1/25 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Y102/02 , C12Y603/02 , G01N33/5011 , G01N33/5023 , G01N33/573 , G01N33/574 , G01N33/57496 , G01N2333/9015 , G01N2333/90203 , G01N2500/04 , G01N2800/52
摘要: The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
-
5.
公开(公告)号:US20170007721A1
公开(公告)日:2017-01-12
申请号:US15043377
申请日:2016-02-12
发明人: Joseph Anderson , Gerhard Bauer
IPC分类号: A61K48/00 , C12N15/86 , A61K38/53 , C12N7/00 , C12N15/113 , A61K31/7105
CPC分类号: A61K48/0066 , A61K31/7105 , A61K38/53 , C07K14/7158 , C12N7/00 , C12N15/1138 , C12N15/86 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12N2320/31 , C12N2320/32 , C12N2740/16011 , C12N2740/16043 , C12N2740/16051 , C12Y603/02
摘要: Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5 alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.
摘要翻译: 含有至少包含慢病毒骨架的重组慢病毒载体,其包含用于整合入靶细胞基因组的必需慢病毒序列; 编码CCR5 RNAi的核酸; 和调节编码CCR5 RNAi元件的核酸表达的表达控制元件由本发明提供。 在另一方面,载体还含有编码TRIM5α和HIV TAR诱饵序列的多核苷酸以及基因表达调控元件,例如与多核苷酸可操作连接的启动子。 将载体与包装质粒和包膜质粒组合,并任选地与细胞特异性靶向抗体缀合。 本文进一步提供了使用组合物的诊断和治疗方法。
-
6.
公开(公告)号:US20150218242A1
公开(公告)日:2015-08-06
申请号:US14418513
申请日:2013-07-31
申请人: INSERM (Institut National de la Sante et de la Recherche Medicale) , CEA , Universite Paris-Sud X1 , Universite Paris Diderot-Paris 7
发明人: Paul-Henri Romeo , Aude Parcelier , Federica Ferri , Vanessa Petit , Nathalie Gault , Daniel Lewandowski
IPC分类号: C07K14/47 , C12Q1/68 , A01K67/027
CPC分类号: C07K14/4705 , A01K67/0275 , A01K67/0276 , A01K2217/075 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/0306 , A01K2267/0368 , A01K2267/0381 , A61K38/00 , C12N9/93 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Y603/02 , G01N33/6872 , G01N2800/7095
摘要: The present invention relates to the prevention or treatment of inflammatory diseases. The present invention also relates to a method for screening a compound capable of promoting or restoring the resolution of inflammation and which may be useful for preventing or treating inflammatory disorders.
摘要翻译: 本发明涉及炎症性疾病的预防或治疗。 本发明还涉及一种筛选能够促进或恢复炎症分辨率并且可用于预防或治疗炎症性疾病的化合物的方法。
-
公开(公告)号:US20150044735A1
公开(公告)日:2015-02-12
申请号:US14390360
申请日:2013-04-03
CPC分类号: C12P17/18 , C07G5/00 , C12N9/0006 , C12N9/0071 , C12N9/1085 , C12N9/93 , C12N15/52 , C12P5/007 , C12Y114/14001 , C12Y205/01 , C12Y603/02
摘要: The biosynthesis of fungal bicyclo[2.2.2]diazaoctane indole alkaloids with a wide spectrum of biological activities have attracted increasing interest. Their intriguing mode of assembly has long been proposed to feature a non-ribosomal peptide synthetase, a presumed intramolecular Diels-Alderase, a variant number of prenyltransferases, and a series of oxidases responsible for the diverse tailoring modifications of their cyclodipeptide-based structural core. Until recently, the details of these biosynthetic pathways have remained largely unknown due to lack of information on the fungal derived biosynthetic gene clusters. Herein, we report a comparative analysis of four natural product metabolic systems of a select group of bicyclo[2.2.2]diazaoctane indole alkaloids including (+)/(−)-notoamide, paraherquamide and malbrancheamide, in which we propose an enzyme for each step in the biosynthetic pathway based on deep annotation and on-going biochemical studies.
摘要翻译: 具有广泛生物活性的真菌双环[2.2.2]二氮杂辛烷吲哚生物碱的生物合成已引起越来越多的兴趣。 长期以来,它们的有趣的装配模式已经被提出以非核糖体肽合成酶,推定的分子内狄尔斯 - 阿尔德酶,异戊烯转移酶的变体数量和一系列负责其基于环二肽的结构核心的多样定制修饰的氧化酶的特征。 直到最近,由于缺乏关于真菌衍生的生物合成基因簇的信息,这些生物合成途径的细节仍然很大程度上是未知的。 在本文中,我们报告了一组选择性双环[2.2.2]二氮杂辛烷吲哚生物碱(包括(+)/( - ) - 乙酰胺,对二甲苯胺和马来酰胺)的天然产物代谢系统的比较分析,其中我们为每个 基于深度注释和持续生物化学研究,生物合成途径的一步。
-
公开(公告)号:US20240141402A1
公开(公告)日:2024-05-02
申请号:US18002349
申请日:2021-06-24
发明人: Kenichiro TABATA , Naoto TSUDA , Yuugo ADACHI
CPC分类号: C12P21/02 , C07K14/001 , C12N9/93 , C12Y603/02
摘要: An object of the present invention is to provide a protein having dipeptide synthesizing activity with improved substrate specificity, and a method in which the protein or a microorganism having ability to produce the protein is used to efficiently produce a target dipeptide while reducing a by-product dipeptide produced in addition to the target dipeptide. According to the present invention, a protein consisting of an amino acid sequence obtained by substituting, with other amino acid residues, amino acid residues corresponding to one or more amino acid residues selected from the group consisting of amino acid residues at positions 107, 108, and 110 in an amino acid sequence set forth in SEQ ID NO: 2, or a mutant protein or a homologous protein of a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 is provided, and a microorganism producing the protein can be used to efficiently produce a dipeptide.
-
公开(公告)号:US20180230449A1
公开(公告)日:2018-08-16
申请号:US15750415
申请日:2016-07-06
申请人: MERCK PATENT GMBH
CPC分类号: C12N9/93 , C12N15/1093 , C12P21/02 , C12Y603/02 , C40B40/06 , C40B40/08
摘要: The present invention concerns a novel method for the modification and/or custom-made design of artificial non-ribosomal peptide synthetases (NRPSs) from naturally available NRPSs. The artificial NRPSs are of predetermined length and amino acid composition and sequence. Via fusion of well-defined NRPS units (so-called “exchange units”) in a certain manner, using a specific sequence motif in the linker areas it is possible to construct artificial and/or modified NRPS assembly lines, which have the ability of synthesizing peptides of a desired structure.
-
公开(公告)号:US20170218353A1
公开(公告)日:2017-08-03
申请号:US15423115
申请日:2017-02-02
申请人: Celgene CAR LLC
发明人: Russell C. Petter , Charles F. Jewell , Kwangho Lee , Aravind Prasad Medikonda , Deqiang Niu , Lixin Qiao , Juswinder Singh , Zhendong Zhu
IPC分类号: C12N9/96 , C12N9/00 , C12N9/12 , C12Q1/37 , C12Q1/48 , G06F19/16 , C07D487/04 , C07D491/08 , C07D405/14 , C07D495/04 , C07D403/14 , C12N9/50 , C12Q1/25
CPC分类号: C12N9/96 , C07D207/16 , C07D239/49 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D417/06 , C07D417/14 , C07D487/04 , C07D491/08 , C07D493/04 , C07D495/04 , C07D513/04 , C07D519/00 , C12N9/12 , C12N9/506 , C12N9/93 , C12Q1/25 , C12Q1/37 , C12Q1/485 , C12Y207/11001 , C12Y304/21098 , C12Y603/02 , G01N33/68 , G16B15/00 , G16C20/50
摘要: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
-
-
-
-
-
-
-
-
-